

Paraic A Kenny

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4997571/paraic-a-kenny-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56

papers

4,351

citations

26

h-index

65

g-index

65

ext. papers

4,876

ext. citations

6.4

avg, IF

5.35

L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 56 | Three-dimensional culture models of normal and malignant breast epithelial cells. <i>Nature Methods</i> , 2007 , 4, 359-65 | 21.6 | 971 |
| 55 | The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. <i>Molecular Oncology</i> , 2007 , 1, 84-96 | 7.9 | 715 |
| 54 | Tumor reversion: correction of malignant behavior by microenvironmental cues. <i>International Journal of Cancer</i> , 2003 , 107, 688-95 | 7.5 | 282 |
| 53 | Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. <i>Journal of Cellular Biochemistry</i> , 2007 , 101, 830-9 | 4.7 | 271 |
| 52 | Store-independent activation of Orai1 by SPCA2 in mammary tumors. <i>Cell</i> , 2010 , 143, 84-98 | 56.2 | 213 |
| 51 | Targeting TACE-dependent EGFR ligand shedding in breast cancer. <i>Journal of Clinical Investigation</i> , 2007 , 117, 337-45 | 15.9 | 203 |
| 50 | ORAI1-mediated calcium influx in lactation and in breast cancer. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 448-60 | 6.1 | 160 |
| 49 | Targeting the tumor microenvironment. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 3468-74 | 2.8 | 158 |
| 48 | miR-21 mediates hematopoietic suppression in MDS by activating TGF- β signaling. <i>Blood</i> , 2013 , 121, 2875-81 | 2.8 | 108 |
| 47 | Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. <i>Cancer Research</i> , 2006 , 66, 7095-102 | 10.1 | 102 |
| 46 | Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2158-68 | 6.1 | 88 |
| 45 | FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3211-20 | 15.9 | 87 |
| 44 | SAT-331 Elucidating the Role of Breast Cancer Specific GATA3 Mutation in Estrogen Receptor Positive Breast Cancer. <i>Journal of the Endocrine Society</i> , 2019 , 3, | 0.4 | 78 |
| 43 | Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. <i>PLoS Computational Biology</i> , 2010 , 6, e1000684 | 5 | 67 |
| 42 | Localization of plasma membrane and secretory calcium pumps in the mammary gland. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 369, 977-81 | 3.4 | 67 |
| 41 | Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2013 , 434, 695-700 | 3.4 | 65 |
| 40 | Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. <i>Journal of Biological Chemistry</i> , 2010 , 285, 37458-66 | 5.4 | 65 |

| | | | |
|----|--|------|----|
| 39 | Altered purinergic receptor-Ca ²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. <i>Molecular Oncology</i> , 2016 , 10, 166-78 | 7.9 | 61 |
| 38 | TACE: a new target in epidermal growth factor receptor dependent tumors. <i>Differentiation</i> , 2007 , 75, 800-8 | 3.5 | 55 |
| 37 | Molecular evolution of immunoglobulin and fibronectin domains in titin and related muscle proteins. <i>Gene</i> , 1999 , 232, 11-23 | 3.8 | 54 |
| 36 | Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. <i>Journal of Biological Chemistry</i> , 2012 , 287, 28598-608 | 5.4 | 53 |
| 35 | Remodeling of purinergic receptor-mediated Ca ²⁺ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells. <i>PLoS ONE</i> , 2011 , 6, e23464 | 3.7 | 46 |
| 34 | GRB7 is required for triple-negative breast cancer cell invasion and survival. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 607-15 | 4.4 | 40 |
| 33 | Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity. <i>Cancer Research</i> , 2009 , 69, 6721-9 | 10.1 | 36 |
| 32 | Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ER ⁺ Positive Breast Cancer. <i>Cancer Research</i> , 2015 , 75, 4830-8 | 10.1 | 27 |
| 31 | Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 411, 107-10 | 3.4 | 26 |
| 30 | TACE-dependent TGF β shedding drives triple-negative breast cancer cell invasion. <i>International Journal of Cancer</i> , 2013 , 133, 2587-95 | 7.5 | 25 |
| 29 | Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. <i>Glycobiology</i> , 2013 , 23, 1477-90 | 5.8 | 23 |
| 28 | Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1287-98 | 6.4 | 23 |
| 27 | Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. <i>Life Sciences</i> , 2018 , 198, 128-135 | 6.8 | 18 |
| 26 | Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7194-203 | 12.9 | 18 |
| 25 | The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. <i>JCI Insight</i> , 2018 , 3, | 9.9 | 17 |
| 24 | Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. <i>Anticancer Research</i> , 2018 , 38, 4435-4441 | 2.3 | 16 |
| 23 | MTORC1/2 Inhibition as a Therapeutic Strategy for Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 346-355 | 6.1 | 13 |
| 22 | SARS-CoV-2 sequencing reveals rapid transmission from college student clusters resulting in morbidity and deaths in vulnerable populations | | 11 |

| | | | |
|----|---|-----|----|
| 21 | PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. <i>Cancer Prevention Research</i> , 2014 , 7, 407-17 | 3.2 | 10 |
| 20 | Normal range of serum Amphiregulin in healthy adult human females. <i>Clinical Biochemistry</i> , 2012 , 45, 460-3 | 3.5 | 10 |
| 19 | Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017 , 1, | 3.6 | 9 |
| 18 | Interregional SARS-CoV-2 spread from a single introduction outbreak in a meat-packing plant in northeast Iowa | | 9 |
| 17 | Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, e433-e438 | 3 | 6 |
| 16 | Clarification of the C-terminal proteolytic processing site of human Amphiregulin. <i>FEBS Letters</i> , 2012 , 586, 3500-2 | 3.8 | 6 |
| 15 | Translating Genomic Research into Clinical Practice: Promise and Pitfalls. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 15-23 | 7.1 | 6 |
| 14 | Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth. <i>Breast Cancer Research</i> , 2018 , 20, 131 | 8.3 | 6 |
| 13 | Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. <i>Experimental and Molecular Pathology</i> , 2019 , 110, 104260 | 4.4 | 4 |
| 12 | Genomic analysis of melanoma evolution following a 30-year disease-free interval. <i>Journal of Cutaneous Pathology</i> , 2017 , 44, 805-808 | 1.7 | 3 |
| 11 | Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-6 | 3.6 | 3 |
| 10 | Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient | | 3 |
| 9 | InferAMP, a python web app for copy number inference from discrete gene-level amplification signals noted in clinical tumor profiling reports. <i>F1000Research</i> , 2019 , 8, 807 | 3.6 | 3 |
| 8 | InferCNV, a python web app for copy number inference from discrete gene-level amplification signals noted in clinical tumor profiling reports. <i>F1000Research</i> , 2019 , 8, 807 | 3.6 | 2 |
| 7 | Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 653-660 | 4.4 | 2 |
| 6 | Outbreak or pseudo-outbreak? Integrating SARS-CoV-2 sequencing to validate infection control practices in an end stage renal disease facility | | 2 |
| 5 | Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. <i>Antibody Therapeutics</i> , 2021 , 4, 252-261 | 5.8 | 1 |
| 4 | Outbreak or pseudo-outbreak? Integrating SARS-CoV-2 sequencing to validate infection control practices in a dialysis facility. <i>American Journal of Infection Control</i> , 2021 , 49, 1232-1236 | 3.8 | 1 |

- | | | | |
|---|--|-----|---|
| 3 | Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022 , 103, 115656 | 2.9 | o |
| 2 | Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors. <i>Analytical Biochemistry</i> , 2018 , 551, 26-28 | 3.1 | |
| 1 | Comparative analysis of GATA3 mutation profiles between Asian and Western patients with breast cancer. Is there really a difference?. <i>Cancer</i> , 2014 , 120, 2778-9 | 6.4 | |